Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Tagworks Pharmaceuticals BV
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Iovance Biotherapeutics, Inc.
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
AstraZeneca
Mayo Clinic
Curtin University
Providence Health & Services
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Oslo University Hospital
National Institutes of Health Clinical Center (CC)
Pfizer
Novartis
Pfizer
Pfizer
AstraZeneca
Turning Point Therapeutics, Inc.
NRG Oncology
Taiho Oncology, Inc.
NRG Oncology
Alterome Therapeutics, Inc.
NRG Oncology
Pheon Therapeutics
Hôpital NOVO
Boston Scientific Corporation
Peking University People's Hospital
Maastricht University Medical Center
Melanoma and Skin Cancer Trials Limited
Boston Scientific Corporation
SillaJen, Inc.
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins